Stem cell transplantation for chronic myeloid leukaemia: The role of infused marrow cell dose

Hematology Journal

Volumn 2, Issue 4, 2001, Pages 265-271

  Pocock, C ^a   Szydlo, R ^a   Davis, J ^a   de la Fuente, J ^a   Craddock, C ^a   Cwynarski, K ^a   Olavarria, E ^a   Rezvani, K ^a   Kanfer, E ^a   Apperley, J ^a   Goldman, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

CML; Marrow cell dose; Prognostic factors; Stem cell transplantation; Unrelated donors

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAUNORUBICIN; HLA ANTIGEN; METHOTREXATE; MITOXANTRONE; POLYCLONAL ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGRAFT; ARTICLE; BONE MARROW CELL; CANCER RADIOTHERAPY; CELL COUNT; CELL NUCLEUS; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DONOR; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN CELL; INFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; RECIPIENT; RELATIVE; SIBLING; SIDE EFFECT; STEM CELL; SURVIVAL; TREATMENT OUTCOME; VOLUNTEER; WHOLE BODY RADIATION;

ADULT; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL COUNT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 17944362060     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200108     Document Type: Article

References (41)

1. Bone marrow transplantation for patients with chronic myeloid leukemia
2. Allogeneic bone marrow transplantation for chronic myeloid leukemia
3. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits
4. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
5. Bone marrow transplantation for chronic myeloid leukemia: Long-term results
6. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: Impact of disease related variables (Sokal score)
7. Results of allogeneic transplants for leukemia using donors other than HLA-identical siblings
8. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: Experience of four marrow transplant centres
9. Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated donors
10. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
11. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first two years
12. The outcome of matched unrelated donor marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, prednisolone
13. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of class II matching
14. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
15. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program
16. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
17. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation
18. Related donor marrow transplant for chronic myeloid leukemia: Patient characteristics predictive of outcome
19. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation
20. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
21. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
22. Cytotoxic T lymphocyte precursor frequency analysis in bone marrow transplantation with volunteer unrelated donors
23. CMV serostatus is a major determinant of outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored GVHD prophylaxis
24. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
25. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus
26. Measurement of cytotoxic T lymphocyte precursor frequencies reveals cryptic HLA class 1 mismatches in the context of unrelated donor bone marrow transplantation
27. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: Changing impact of risk factors
28. Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality
29. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: An important modifiable factor influencing outcome
30. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose
31. 1994 consensus conference on acute GVHD grading
32. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
33. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia
34. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia
35. Relapse after non T cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation, use of an unrelated donor and chronic graft versus host disease are predictive
36. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
37. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
38. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
39. Improved immune reconstitution after allotransplantation of peripheral stem cells instead of bone marrow
40. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease
41. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - An analysis of engraftment and GVHD risk